X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Aphaia's primary drug candidate is APHD-012 (dextrose), a proprietary oral glucose formulation, currently undergoing mid-stage clinical trials for treating patients with obesity.
Lead Product(s): Dextrose
Therapeutic Area: Nutrition and Weight Loss Product Name: APHD-012
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
APH-012 (dextrose) is a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. It is being evaluated for chronic weight management in patients with obesity and to improve glucose tolerance in patients with prediabetes.
Lead Product(s): Glucose
Therapeutic Area: Endocrinology Product Name: APH-012
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
APH-012 is a glucose formulation designed to be released at discrete parts of the small intestine to restore endogenous nutrient-sensing signaling pathways and stimulate the release of the broad spectrum of enteric hormones that control multiple homeostatic functions.
Lead Product(s): Glucose
Therapeutic Area: Nutrition and Weight Loss Product Name: APH-012
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
